Healthcare ❯ Pharmaceuticals

Weight Loss

GLP-1 Medications GLP-1 Drugs Medications Drugs GLP-1 Injections GLP-1 Program Treatment Comparison Body Weight Percentage Semaglutide GLP-1 Hormones Obesity Treatments Health-Tech Partnerships GLP-1 Treatments GLP-1 Products Wegovy Drug Development GLP-1 Market Competition

Novo Nordisk Sues Lilly Over Weight‑Loss Ads as GLP‑1 Rivalry Intensifies

The case seeks to curb Eli Lilly’s consumer ads and could change how head‑to‑head trial results are shown to patients and prescribers.

Novo Nordisk Lifts 2026 Outlook as Wegovy Pill Powers Big Q1 Beat

GSK Gains After Cramer Endorsement as Company Pushes Into Weight-Loss Drugs

Eli Lilly Tightens GLP-1 Grip, Guides Up to $83 Billion for 2026

Eli Lilly’s Q4 Beat and Bullish Outlook Give Way to Stock Drop on Low-Cost GLP-1 Pills

Novo Nordisk Presses India Expansion and Higher-Dose Push as Analyst Views Diverge